Recent Updates
Recently added Catalysts

TNG462 vopimetostat

Phase 1/2

ALK Positive Non-small Cell Lung Cancer | Small Molecules | Oncology |Tango Therapeutics, Inc.|Trials Updated: Nov 16, 2026

TNG462 vopimetostat development status

Highest phase Phase 1/2 run by Tango Therapeutics, Inc. (NCT07897734)
Phase scored for TNGXPhase 1
Registered trials 2 across 2 sponsors since Oct 2026

TNG462 vopimetostat target and mechanism

ModalitySmall Molecules

Also known as vopimetostat

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

TNG462 vopimetostat clinical trials

TNG462 vopimetostat · 1 trial · 1 indication

Phase 1 1
NCT07938463Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLCALK Positive Non-small Cell Lung Cancer
NOT YET_RECRUITING30 Analytics
PHASE1NOT YET_RECRUITING
Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC
ALK Positive Non-small Cell Lung CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
Up to 28 days.

A DLT is defined as a treatment-emergent adverse event occurring during Cycle 1 that is considered at least possibly related to TNG462, lorlatinib, or the combination and is not clearly attributable to underlying disease, intercurrent illness, or concomitant medications. DLTs include Grade ≥3 non-hematologic toxicities with specified exceptions for transient or manageable events; clinically significant hepatic, pulmonary, pancreatic, cardiac, ECG, CNS, or neurocognitive toxicities; Grade 4 hematologic toxicities; Grade ≥3 febrile neutropenia; Grade ≥3 thrombocytopenia with clinically significant bleeding; prolonged treatment-related hematologic toxicity requiring interruption of both study drugs for \>14 consecutive days; any toxicity resulting in permanent discontinuation of both study drugs during Cycle 1 due to safety concerns; and any death at least possibly related to study treatment during the DLT assessment period.

Maximum Tolerated Dose (MTD) of TNG462
Up to 28 days.

The study uses a Backfill Bayesian Optimal Interval (BF-BOIN) design to determine the MTD of TNG462. TNG462 will start at 200 mg QD and may be escalated to 250 mg QD at the optional Dose Level 3 if Dose Level 2 is tolerated, at the discretion of the Sponsor-Investigator.

MTD of Lorlatinib
Up to 28 days.

The study uses a BF-BOIN design to determine the MTD of Lorlatinib. Lorlatinib will start at 50 mg QD and may be escalated to 75 mg QD at Dose Level 2 if Dose Level 1 is tolerated. Lorlatinib will remain at 75 mg QD at the optional Dose Level 3.

Recommended Phase II Dose (RP2D) of TNG462 in Combination with Lorlatinib
Up to 28 days.

The study uses a BF-BOIN design to determine the MTD. The RP2D is selected from among acceptable dose levels at or below the MTD based on the totality of safety, tolerability, pharmacokinetic, and preliminary antitumor activity data obtained during Phase I.

Secondary Endpoints

Objective response rate (ORR)
Tumor measurements are repeated every 2 cycles for the first 6 months and every 3 cycles thereafter.
Duration of Overall Response (DOR)
From date of first documented CR/PR until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Median progression-free survival (PFS)
From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TNG462 plus LorlatinibEXPERIMENTALParticipants receive TNG462 once daily and lorlatinib once daily according to the study treatment plan and study calendar.

Interventions

NameTypeDescription
TNG462 vopimetostatDRUGInvestigational drug Supplier/manufacturer: Tango Therapeutics
LorlatinibDRUGSource/manufacturer: Commercial supply / Pfizer
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Age ≥ 18 years * Histologically or cytologically confirmed NSCLC harboring an ALK rearrangement, documented by an FDA/EMA-approved or validated local test. * Confirmed MTAP loss, demonstrated by immunohistochemistry (IHC) as complete loss in the presence of a positive internal...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 16, 2026NCT07938463New Trial Detected: Not Yet Recruiting